Compare GIS & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GIS | GNLX |
|---|---|---|
| Founded | 1866 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.2B | 133.0M |
| IPO Year | 2004 | 2022 |
| Metric | GIS | GNLX |
|---|---|---|
| Price | $39.20 | $2.74 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 4 |
| Target Price | ★ $42.07 | $17.25 |
| AVG Volume (30 Days) | ★ 8.6M | 256.0K |
| Earning Date | 03-18-2026 | 05-12-2026 |
| Dividend Yield | ★ 7.08% | N/A |
| EPS Growth | N/A | ★ 9.47 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,037,800,000.00 | $8,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.11 | N/A |
| 52 Week Low | $31.75 | $2.29 |
| 52 Week High | $51.33 | $8.54 |
| Indicator | GIS | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 65.73 | 46.01 |
| Support Level | $35.45 | $2.39 |
| Resistance Level | $39.56 | $3.05 |
| Average True Range (ATR) | 1.00 | 0.20 |
| MACD | 0.23 | -0.02 |
| Stochastic Oscillator | 97.73 | 37.93 |
General Mills is a global packaged-food company that produces snacks, cereal, convenient meals, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Pillsbury, Betty Crocker, Blue Buffalo, and Haagen-Dazs. In fiscal 2025, 81% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. Although most of General Mills' products are sold through retail stores to consumers, the company also sells products to the foodservice channel and the commercial baking industry.
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.